Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
14,477 total articles
Nvidia's leadership in AI compute makes it the natural partner for software platforms like Palantir. If a commercial partnership or strategic deal surfaces, NVDA should see meaningful re-rating. This trade idea lays out a mid-term swing entry at $197.81, a stop at $185.00 and a primary target at $236.54 (52-week high), with clear catalysts and a ri…
ICICI Bank (IBN) looks positioned to benefit from a favorable policy backdrop and improving loan demand. Technical momentum and reasonable valuation metrics support a tactical long over the next 45 trading days. Entry $29.50, target $34.50, stop $28.00.
Nvidia remains the dominant supplier of AI compute and networking hardware with industry-leading margins, massive free cash flow and a fortress balance sheet. At $195, the stock offers a tactical long opportunity for disciplined traders: entry $195.00, stop $170.00, target $260.00 over a long-term 180 trading day horizon. The upside is driven by co…
Achieve Life Sciences (ACHV) carries headline risk from a recent Complete Response Letter, but fundamentals and setup support a constructive position trade. The company still commands a market cap near $660M, has a meaningful NDA timeline and $45M capital raise behind the program. We outline an explicit entry, stop and $12 target on a 180-trading-d…
Gorman-Rupp sells pumps — but recent demand from data-center cooling and infrastructure has turned this sleepy small-cap into a volatile, opportunity-rich name. Valuation looks full at ~38x earnings, yet cash flow, a healthy balance sheet and a tight float mean a disciplined, mid-term long can pay off. Below: why I’m watching GRC, the concrete trad…
Bioventus (BVS) has stronger cash generation, a cleaner credit profile and an end-market tailwind behind osteoarthritis and fracture-healing therapies. At roughly $11.69 today and a market cap near $1.0B, the stock looks fairly valued vs. fundamentals but offers an asymmetric swing trade: buy now for a re-rating toward a mid-30s P/E as execution an…
CoreWeave has pulled back sharply despite accelerating AI infrastructure demand and a scalable, capex-efficient model. We upgrade to Buy and lay out a core trade with clear entry, stop and targets across horizons. The setup favors disciplined size and patience given short-term volatility.
GoDaddy (GDDY) is trading well below its prior highs, but the market has likely overreacted to headline risk and is underestimating the company's ability to monetize AI in its Applications & Commerce segment. With free cash flow of $1.64B, a price-to-free-cash-flow near 7, and a PE roughly 13-14x, the setup supports a long trade with defined risk a…
Nu Holdings is one of the fastest-growing digital banks in Latin America with 135 million customers and Q1 2026 revenue of $5.32 billion. The growth runway is large, but currency, credit and execution risks are real. This trade idea lays out a disciplined long entry with a $13.80 pivot, a $11.50 stop and a $19.00 target over a 180-trading-day horiz…
Technip Energies (THNPY) is an engineering-and-technology play on energy transition projects (LNG, SAF, hydrogen and refinery modernization). The stock looks reasonable on valuation - market cap ~$7.19B, P/E ~17 and a 2.1% yield - but technicals and recent strength argue for patience. I prefer to buy a pullback to $37.50 with a $34.50 stop and $48.…
Urban Outfitters is posting stronger comps than many apparel peers, delivering record quarterly revenue and expanding subscription growth. The stock trades at a reasonable multiple versus growth and offers an asymmetric risk/reward for a mid-term swing trade. Technicals are mixed, so position sizing and a tight stop matter.
Altimmune ($ALT) is worth revisiting on a trade basis. Recent 48-week MASH data and a refreshed balance sheet remove near-term financing as the main drag. A potential AUD (alcohol use disorder) readout expected in Q3 2026 is a binary catalyst that could re-rate the stock toward prior highs if positive. We upgrade to a tactical long with defined ent…
Shift4 (FOUR) has evolved beyond card rails into a structurally defensive niche after the Global Blue acquisition. Strong free cash flow, accelerating payment volumes, and insider buying create a high-conviction long. Risks include heavy leverage, integration execution and macro pressure on travel spend. I recommend a long entry at $51.47 with $46.…
IREN has reappeared in takeover chatter. The market is pricing in a deal that is not yet signed — creating a defined, asymmetric trade: buy weakness now with a strict stop and a mid-term target reflecting a likely takeover premium. This idea sizes for conviction but includes a clear exit if the paperwork never arrives.
Universal Music's advantages in catalog breadth, artist relationships and emerging AI licensing create a clearer path to margin expansion and revenue upside than two years ago. This note lays out an actionable long trade with entry, stop and targets and explains the key catalysts and risks that should move the stock.
First Quantum (FQVLF) has swung from panic to opportunity. The stock trades well below its 52-week high despite a market-cap of roughly $22.1B and a clear exposure to the copper story. Political perception has weighed on the multiple; with commodity tailwinds, rate support and an improving technical base, this is a risk-managed long idea targeting …
American Financial Group has the balance sheet and free cash flow to support baby-bond related capital moves. With the stock trading at a reasonable multiple, a buy here offers roughly 15% upside to my target while collecting a mid-single-digit yield. I outline an actionable trade plan, key catalysts and risks.
Crescent Energy is trading at roughly 8x price-to-free-cash-flow with an implied FCF yield north of 12% and a >5% cash distribution. With enterprise-value multiples under 5x EBITDA and projected merger synergies of $90-100M, this name looks attractively priced versus the risk of a cyclical earnings drag. I present an actionable long trade with entr…
Coinbase is the dominant regulated gateway for institutions entering crypto markets. Recent weakness offers an opportunity to buy a prime-brokerage style business exposed to rising institutional flows, stablecoin partnerships, and onchain product revenue. This trade targets a recovery toward $220 over 180 trading days with a strict stop at $145 to …
ANTA Sports (ANPDF) sits at a technical and sentiment inflection point. Deeply oversold indicators, episodic heavy shorting, and a plausible M&A narrative tied to Puma create a tradeable asymmetric risk-reward. This plan outlines an entry at $8.87, a stop at $7.50, and a $16.50 target with horizon clarity and explicit risks.
Lumentum (LITE) sits at the center of the silicon-photonics story: huge headline investments, a factory buildout, and promises of hyperscaler orders. The market has dutifully bid the multiple to nosebleed levels - P/E north of 120, EV/EBITDA ~92x and FCF yield around 0.2%. That leaves room for a tactical short over the next 45 trading days if order…
Palo Alto Networks (PANW) sits at the intersection of traditional network security and the emergent need to defend AI attack surfaces. The stock pulled back from $357.53 to trade near $345.81 after a one-day gap, creating a tactical entry for a mid-term swing. Valuation is rich but defendable given platform positioning, recurring revenue mix and so…
Novartis ($156.74) is actively rebuilding its innovation engine with bolt-on M&A and late-stage assets. A clinical readout for a late-stage program (pelacarsen) is expected imminently, and the company just agreed to acquire Myricx Bio for up to $1.5 billion (07/06/2026) to beef up its ADC payload capabilities. We view the risk/reward as favorable f…
Uber's platform economics, sizable free cash flow, and explicit supply deals with autonomous vehicle makers mean robotaxis are a real earnings lever, not just a headline. I lay out an actionable long trade with entry, stop, targets, catalysts and risks tied to deployments and regulation.
Strata Critical Medical (SRTA) combines air logistics with newly integrated perfusion and donor services to create a vertically aligned organ-transplant platform. The Keystone Perfusion deal and guidance for high-teens Adjusted EBITDA growth underpin a mid-term long trade: buy SRTA around current levels with a $7.00 target and a disciplined stop at…
